Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA - Endpoints News
Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA Endpoints News
... → Pittsburgh-based Krystal Biotech $KRYS has won the EMA's Prime status for its gene therapy to treat dystrophic epidermolysis bullosa. The company says ...
Comments
Post a Comment